Skip to main content
RMD logo

ResMed Inc. (RMD) Stock: Price, Forecast & Analyst Target

ResMed Inc. (RMD) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $242.61 (+2.00%), as of the Nov 18, 2026 trading session; market cap $34.1B. Expected results Jan 28, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$242.61 +$4.76 (+2.00%) Market Cap $34.1B

ResMed Inc. · RMD · NYSE · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-12: ResMed sells sleep and respiratory devices, masks and accessories, then connects them to patient-monitoring software and a smaller out-of-hospital care platform. Its durability depends on whether that combined ecosystem can keep expanding while portfolio changes and renewed margin pressure interrupt the recent profit trajectory.

Price as of Nov 18, 2026

Key Statistics

95 of 100

MoonshotScore v2 · ResMed (RMD)

Exceptional
Business Quality Elite (94)
Financial Safety Fortress (95)
Valuation Full (52)
Growth Durability Compounding (83)
Momentum Surging (81)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 7 of the last 8 reports
  • expected results Jan 28, 2027
  • Altman Z 11.99 · Piotroski F 7

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RMD (57 recorded, newest six shown)
RecordedScoreBand
95Exceptional
90Exceptional
95Exceptional
95Exceptional
95Exceptional
95Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$242.61
Change on the day+2.00%
52-week range$180.27–$277.67
Market capitalisation$34.1B—
Price / earnings (trailing)21.60
Shares traded on the day1.22M
Beta (volatility vs the S&P 500)0.76

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $189, high $272, latest $243. $272 $189 high $272 Oct 17, 2025 Nov 18, 2026 · $243 $268Oct 17, 2025$247Oct 31, 2025$244Nov 14, 2025$256Nov 28, 2025$252Dec 12, 2025$245Dec 26, 2025$252Jan 9, 2026$252Jan 23, 2026$272Feb 6, 2026$259Feb 20, 2026$253Mar 6, 2026$226Mar 20, 2026$224Apr 2, 2026$228Apr 17, 2026$205May 1, 2026$202May 15, 2026$191May 29, 2026$195Jun 12, 2026$200Jun 26, 2026$204Jul 10, 2026$195Jul 24, 2026$212Aug 7, 2026$232Aug 21, 2026$228Sep 4, 2026$225Sep 18, 2026$219Oct 2, 2026$239Oct 16, 2026$230Oct 30, 2026$240Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for ResMed (RMD): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Debt/Equity Moderate
ROE Strong
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is ResMed (RMD), and what does it report?

Short answer · as of

ResMed is primarily a sleep and respiratory care business, not a general medical-instrument supplier. Demand comes through sleep clinics, home healthcare dealers and hospitals for therapy devices, ventilation equipment, diagnostics, masks, headgear and related accessories, while AirView, myAir and other connected tools support monitoring, adherence and provider workflows.

Reporting pairs the dominant Sleep and Respiratory Care operation with SaaS. Brightree, MatrixCare and HEALTHCAREfirst extend the company into business management, care records, billing and analytics for organizations delivering care outside hospitals, but device-related revenue remains the larger economic engine.

2 · Latest results

What do the latest results show for ResMed (RMD)?

Revenue reached a new high in the latest reported period, but gross profit, operating profit, net income and diluted earnings eased from the immediately preceding period. The top line therefore expanded without producing sequential profit growth, even as the longer annual record shows revenue and net income advancing throughout the displayed span and research spending rising alongside them.

Management expects annual revenue to keep growing, while warning of near-term gross-margin contraction and roughly flat operating-expense dollars. It also frames underlying seasonality after excluding the MatrixCare divestiture, the Noctrix acquisition and Astral revenue, so reported growth and underlying operating momentum may not move together cleanly.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$1.34B$349M$2.37 (diluted)
Q2 FY2026$1.42B$393M$2.68 (diluted)
Q3 FY2026$1.43B$399M$2.74 (diluted)
Q4 FY2026$1.46B$383M$2.64 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ResMed (RMD)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Positive operating cash flow across the displayed periods and cash above total debt give ResMed substantial financial flexibility. Cash has retreated from its recent peak but remains far above earlier levels in the series, while liquidity and distress screens indicate limited near-term balance-sheet strain.

The sharper risk sits in operating leverage rather than solvency. Profit measures fell sequentially despite higher revenue in the latest period, management expects gross-margin pressure, and the market value stands far above net cash; continued execution therefore matters more to the valuation than asset backing.

4 · What to check next?

What should you watch next at ResMed (RMD)?

Short answer · as of

The next earnings report is expected on Jan 28, 2027.

Revenue in the forthcoming report should be read against management’s annual growth range and its warning that normal seasonality is returning on an adjusted portfolio basis. The useful test is whether demand remains aligned with the longer growth path after separating MatrixCare, Noctrix and Astral effects.

Margin conversion deserves equal attention: compare gross profit with revenue, then check whether operating expenses remain near management’s indicated level. Recent earnings generally cleared expectations, but the latest sequential decline in profit makes the composition of the next result more informative than another headline beat.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does ResMed compare with its peers?

Short answer

ResMed's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

ResMed combines therapy hardware and replacement accessories with software that follows patients and devices after deployment. That differs from a pure equipment maker because AirView and myAir connect monitoring, setting adjustments, troubleshooting and adherence support to the installed therapy base.

The company also reaches beyond respiratory treatment through software for home medical equipment providers, pharmacies, senior living, skilled nursing, home health and hospice operators. SaaS broadens the workflow exposure, but Sleep and Respiratory Care remains much larger, so ResMed’s economics are still anchored in devices, masks and the channels that distribute them.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ResMed (RMD) — this page$242.61$34.1B95
Intuitive Surgical, Inc. (ISRG) Same industry, near in market value$420.95 Nov 18, 2026$146B94 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$278.35 Nov 18, 2026$64.3B88 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Named competitor$177.33 Nov 18, 2026$50.0B83 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Named competitor$75.23 Nov 18, 2026$36.1B80 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$141.67 Nov 18, 2026$8.98B77 5-pillar Nov 18, 2026
Haleon plc (HLN) Named competitor$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Medline Inc. Class A Common Stock (MDLN) Same industry, near in market value$39.16 Nov 18, 2026$51.5B72 5-pillar Nov 18, 2026
Repligen Corporation (RGEN) Same industry, near in market value$172.67 Nov 18, 2026$11.0B71 5-pillar Nov 18, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$15.37 Nov 18, 2026$10.4B71 5-pillar Nov 18, 2026
Becton, Dickinson and Company (BDX) Named competitor$216.04 Nov 18, 2026$58.9B68 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$165.85 Nov 18, 2026$6.58B61 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$213.00 – $300.00
Consensus target
$246.89
Median target
$230.00

Consensus record · Captured .

Measured against a quoted price of $242.61 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 15 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
15
Identified insiders
6
Purchases
0
Sales
1
Other transactions
14

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RMD in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RMD in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about ResMed (RMD)?

Read these with our analysis →

What Investors Ask About ResMed (RMD) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does ResMed sell besides sleep apnea machines?

ResMed sells masks, headgear, ventilation and diagnostic equipment, dental devices, connectivity modules and related accessories. It also supplies cloud software for patient management and operational workflows across home-based and post-acute care.

How do AirView and myAir fit ResMed’s device business?

AirView lets clinicians monitor connected devices and adjust settings remotely, while myAir gives sleep apnea patients education, troubleshooting and adherence support. Together they extend ResMed’s relationship with providers and patients beyond the initial device delivery.

How does the MatrixCare divestiture affect ResMed’s growth comparisons?

Management excludes the MatrixCare divestiture, along with the Noctrix acquisition and Astral revenue, when describing underlying seasonality. Reported revenue growth should therefore be separated from portfolio effects before judging demand momentum.

Can ResMed support its recently increased dividend from internal cash generation?

Operating cash flow has remained positive across the displayed periods, and cash exceeds total debt. The higher declared distribution therefore sits alongside strong liquidity and ongoing internal cash generation.

What is the RMD stock price today?

The last price recorded for ResMed Inc. (RMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RMD price target?

The analyst consensus price target for ResMed Inc. (RMD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Management outlook — dated call excerpts
  • 1. What is ResMed (RMD), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for ResMed (RMD)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for ResMed (RMD)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Distress and quality screens; Quarterly income statement (USD thousands); Management outlook — dated call excerpts; Cash against market value; Trailing twelve-month ratio set
  • 4. What should you watch next at ResMed (RMD)?: Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • 5. How does ResMed compare with its peers?: Business description; Revenue by segment
  • FAQ: What does ResMed sell besides sleep apnea machines?: Business description
  • FAQ: How do AirView and myAir fit ResMed’s device business?: Business description
  • FAQ: How does the MatrixCare divestiture affect ResMed’s growth comparisons?: Management outlook — dated call excerpts
  • FAQ: Can ResMed support its recently increased dividend from internal cash generation?: Next scheduled dividend; Recent dividends paid; Operating cash flow by quarter (USD millions); Cash, investments and debt
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold RMD

Funds in our ETF coverage that list RMD among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
LGHT ETF10.58%